BJMO - volume 8, issue 4, september 2014
H. Wildiers MD, PhD, H. Denys MD, PhD, C. Fontaine MD, A. Awada MD, PhD
Knowledge on adjuvant and neoadjuvant chemotherapy regimens in breast cancer is increasing rapidly. Many different regimens are available: some have been compared with each other, but still many questions remain to be answered. At the breast cancer task force meeting of the Belgian Society of Medical Oncology (BSMO) in Brussels, on February 21st 2014, 41 medical oncologists involved in breast cancer management reviewed the most important recent data. The task force discussed a framework for regimen selection in clinical practice. The authors of this paper summarised the literature and meeting discussion, highlighting controversial areas.
(BELG J MED ONCOL 2014;8(4):116–24)
Read more
BJMO - volume 8, issue 3, july 2014
S. Jeurissen MD, S. Bral MD, PhD, K. Vandecasteele MD, PhD, G. De Meerleer MD, PhD, H. Denys MD, PhD
A 53-year old woman presented with an ovarian cancer, FIGO stage IIIc, for which she received a (suboptimal) debulking. Chemotherapy was started, consisting of three-weekly carboplatin-paclitaxel. After four cycles, an interval-debulking was done, which revealed one positive lymph node (out of 21) located interaortocaval. Chemotherapy was resumed, until seven cycles. She had a complete remission, but after four years, she developed positive mediastinal and interaortocaval lymph nodes. She was treated with stereotactic radiotherapy, which resulted in resolution of the lesions and normalisation of the tumour marker. She has no signs of relapse after nearly two years.
This case illustrates that radiotherapy can be an important treatment option in selected patients with oligometastases.
(BELG J MED ONCOL 2014;8(3):87–90)
Read more
Top
